Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zileuton extended release is an oral small molecule drug used for the prevention and long-term management of asthma in adults and children aged 12 years and older. It is not indicated for the relief of acute asthma attacks. Zileuton's mechanism of action involves selective inhibition of 5-lipoxygenase, an enzyme critical to leukotriene synthesis from arachidonic acid. By blocking leukotriene formation (including LTB4, LTC4, LTD4, LTE4), it reduces airway inflammation, bronchoconstriction, edema, and mucus secretion associated with asthma. The drug is generally well-tolerated but can cause liver enzyme elevations; regular monitoring of liver function is recommended during therapy[1][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zileuton extended release.